S&P 500   4,592.03 (+1.18%)
DOW   35,254.94 (+1.95%)
QQQ   383.49 (+0.09%)
AAPL   165.88 (+2.50%)
MSFT   322.19 (-0.25%)
FB   314.61 (+2.53%)
GOOGL   2,841.58 (+0.05%)
AMZN   3,433.77 (+1.30%)
TSLA   981.02 (-3.34%)
NVDA   291.05 (-5.17%)
BABA   120.51 (+7.64%)
NIO   31.89 (-0.81%)
CGC   9.92 (-0.70%)
AMD   135.22 (-6.10%)
GE   96.57 (+4.10%)
MU   81.88 (+0.32%)
T   23.51 (+0.21%)
F   19.25 (+0.57%)
DIS   150.07 (+2.63%)
PFE   52.18 (-3.85%)
AMC   28.38 (-2.17%)
ACB   5.84 (+0.34%)
BA   206.00 (+3.78%)
S&P 500   4,592.03 (+1.18%)
DOW   35,254.94 (+1.95%)
QQQ   383.49 (+0.09%)
AAPL   165.88 (+2.50%)
MSFT   322.19 (-0.25%)
FB   314.61 (+2.53%)
GOOGL   2,841.58 (+0.05%)
AMZN   3,433.77 (+1.30%)
TSLA   981.02 (-3.34%)
NVDA   291.05 (-5.17%)
BABA   120.51 (+7.64%)
NIO   31.89 (-0.81%)
CGC   9.92 (-0.70%)
AMD   135.22 (-6.10%)
GE   96.57 (+4.10%)
MU   81.88 (+0.32%)
T   23.51 (+0.21%)
F   19.25 (+0.57%)
DIS   150.07 (+2.63%)
PFE   52.18 (-3.85%)
AMC   28.38 (-2.17%)
ACB   5.84 (+0.34%)
BA   206.00 (+3.78%)
S&P 500   4,592.03 (+1.18%)
DOW   35,254.94 (+1.95%)
QQQ   383.49 (+0.09%)
AAPL   165.88 (+2.50%)
MSFT   322.19 (-0.25%)
FB   314.61 (+2.53%)
GOOGL   2,841.58 (+0.05%)
AMZN   3,433.77 (+1.30%)
TSLA   981.02 (-3.34%)
NVDA   291.05 (-5.17%)
BABA   120.51 (+7.64%)
NIO   31.89 (-0.81%)
CGC   9.92 (-0.70%)
AMD   135.22 (-6.10%)
GE   96.57 (+4.10%)
MU   81.88 (+0.32%)
T   23.51 (+0.21%)
F   19.25 (+0.57%)
DIS   150.07 (+2.63%)
PFE   52.18 (-3.85%)
AMC   28.38 (-2.17%)
ACB   5.84 (+0.34%)
BA   206.00 (+3.78%)
S&P 500   4,592.03 (+1.18%)
DOW   35,254.94 (+1.95%)
QQQ   383.49 (+0.09%)
AAPL   165.88 (+2.50%)
MSFT   322.19 (-0.25%)
FB   314.61 (+2.53%)
GOOGL   2,841.58 (+0.05%)
AMZN   3,433.77 (+1.30%)
TSLA   981.02 (-3.34%)
NVDA   291.05 (-5.17%)
BABA   120.51 (+7.64%)
NIO   31.89 (-0.81%)
CGC   9.92 (-0.70%)
AMD   135.22 (-6.10%)
GE   96.57 (+4.10%)
MU   81.88 (+0.32%)
T   23.51 (+0.21%)
F   19.25 (+0.57%)
DIS   150.07 (+2.63%)
PFE   52.18 (-3.85%)
AMC   28.38 (-2.17%)
ACB   5.84 (+0.34%)
BA   206.00 (+3.78%)
NASDAQ:FDMT

4D Molecular Therapeutics News Headlines

$22.16
-0.62 (-2.72%)
(As of 12/6/2021 12:14 PM ET)
Add
Compare
Today's Range
$21.97
$22.98
50-Day Range
$21.42
$36.04
52-Week Range
$20.94
$55.11
Volume
5,854 shs
Average Volume
173,270 shs
Market Capitalization
$712.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Media Mentions By Week



4D Molecular Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

FDMT
News Sentiment

0.88

0.35

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

FDMT Articles
This Week

3

0

FDMT Articles
Average Week

Get 4D Molecular Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.

4D Molecular Therapeutics (NASDAQ:FDMT) News Headlines Today

SourceHeadline
MarketBeat logoShort Interest in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Declines By 26.3%
americanbankingnews.com - December 3 at 11:56 AM
MarketBeat logo4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up to $21.42
americanbankingnews.com - November 30 at 1:28 PM
nasdaq.com logoInsiders who placed huge bets on 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) earlier this year would be disappointed with the 6.9% drop
nasdaq.com - November 26 at 2:30 AM
finance.yahoo.com logoWhat You Need To Know About 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) Investor Composition
finance.yahoo.com - November 25 at 11:27 AM
MarketBeat logo4D Molecular Therapeutics (NASDAQ:FDMT) Hits New 52-Week Low at $21.26
americanbankingnews.com - November 24 at 11:58 AM
finance.yahoo.com logo4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference
finance.yahoo.com - November 23 at 8:22 PM
MarketBeat logo4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down to $24.15
americanbankingnews.com - November 19 at 10:50 AM
MarketBeat logo4D Molecular Therapeutics (NASDAQ:FDMT) Issues Quarterly Earnings Results
americanbankingnews.com - November 11 at 7:42 PM
finance.yahoo.com logo4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights
finance.yahoo.com - November 10 at 4:44 PM
finance.yahoo.com logo4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - October 26 at 7:05 PM
finance.yahoo.com logo4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia
finance.yahoo.com - October 25 at 5:14 PM
barrons.com logo4D Molecular Therapeutics Inc.
barrons.com - October 15 at 12:48 AM
nasdaq.com logo2 Catalysts That Could Move The Share Price Of 4D Molecular Therapeutics In Q4
nasdaq.com - October 12 at 2:16 PM
finance.yahoo.com logo4D Molecular (FDMT) to Start Studies on Cystic Fibrosis, Wet AMD
finance.yahoo.com - October 7 at 2:06 PM
finance.yahoo.com logo4D Molecular Therapeutics to Participate in Chardan’s 5th Annual Genetic Medicines Conference
finance.yahoo.com - September 29 at 6:51 PM
finance.yahoo.com logo4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Meeting
finance.yahoo.com - September 24 at 11:39 AM
finance.yahoo.com logoIs 4D Molecular Therapeutics, Inc. (FDMT) A Good Stock To Buy?
finance.yahoo.com - July 27 at 8:23 AM
nasdaq.com logoRevenue Downgrade: Here's What Analysts Forecast For 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)
nasdaq.com - June 28 at 6:33 PM
finance.yahoo.com logoNewsflash: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Analysts Have Been Trimming Their Revenue Forecasts
finance.yahoo.com - June 28 at 6:33 PM
finance.yahoo.com logo4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and License Agreement
finance.yahoo.com - June 24 at 8:18 AM
finance.yahoo.com logo4D Molecular Therapeutics Appoints Carolyne Zimmermann as Chief Business Officer
finance.yahoo.com - June 7 at 9:40 AM
finance.yahoo.com logo4D Molecular Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
finance.yahoo.com - June 3 at 8:53 AM
finance.yahoo.com logo4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights
finance.yahoo.com - May 14 at 12:04 AM
finance.yahoo.com logo4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME
finance.yahoo.com - May 12 at 9:11 PM
finance.yahoo.com logo4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insiders Increased Their Holdings
finance.yahoo.com - May 10 at 4:00 PM
finance.yahoo.com logo4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform
finance.yahoo.com - May 4 at 8:20 PM
finance.yahoo.com logo4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference
finance.yahoo.com - April 30 at 9:29 AM
finance.yahoo.com logo4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate Studies
finance.yahoo.com - April 27 at 5:52 PM
finance.yahoo.com logoIs FDMT Stock A Buy or Sell?
finance.yahoo.com - April 26 at 3:08 PM
nasdaq.com logoWhat Kind Of Shareholders Hold The Majority In 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) Shares?
nasdaq.com - April 17 at 5:27 PM
finance.yahoo.com logo4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights
finance.yahoo.com - March 25 at 6:10 PM
finance.yahoo.com logoWe Think 4D Molecular Therapeutics (NASDAQ:FDMT) Can Afford To Drive Business Growth
finance.yahoo.com - March 11 at 8:12 AM
marketwatch.com logoGenetic Modification Therapies Market Share, Development by Companies Outlook, Growth Prospects and Key Opportunities by 2030
marketwatch.com - March 11 at 1:08 AM
finance.yahoo.com logo4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry Disease
finance.yahoo.com - March 9 at 9:09 AM
nasdaq.com logo4D Molecular Therapeutics, Inc. Common Stock (FDMT)
nasdaq.com - January 31 at 12:42 AM
finance.yahoo.com logoBioAtla Is the Latest Biotech IPO to Pop
finance.yahoo.com - December 16 at 6:39 PM
Get 4D Molecular Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.